Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ImageneBio, Inc.IKNA · Entity 7139 | Director · President & CEO | February 01, 2024 | February 02, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ImageneBio, Inc.
Report date February 01, 2024 · Filed February 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.36 · Expires 2034-02-01 | Direct | 320,000 |
Reported balance
After 2024-02-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-01 · Grant · Acquired 320,000 · Balance 320,000 F1: 25% of the shares subject to this option shall vest and become exercisable on January 1, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to this option shall vest and become exercisable on January 1, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2024 Filed Feb 2, 2024 17:07 UTC | ImageneBio, Inc. IKNA · Entity 7139 | GrantStock Option (Right to Buy) · Derivative | 320,000 | $0.00 Strike: $1.36 | $0.00 |
DisclosureSEC source: 0000950170-24-010599 · ownership.xml · derivative · entry 1 Manfredi Mark · CIK 0001848547 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 320,000 Underlying: Common Stock · 320,000 shares Expires 2034-02-01 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on January 1, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 16:15 UTC | ImageneBio, Inc. IKNA · Entity 7139 | GrantStock Option (Right to Buy) · Derivative | 220,000 | $0.00 Strike: $2.62 | $0.00 |
DisclosureSEC source: 0000899243-23-000984 · doc4.xml · derivative · entry 1 Manfredi Mark · CIK 0001848547 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,000 Underlying: Common Stock · 220,000 shares Expires 2033-01-03 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on January 1, 2024, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| February 03, 2022 Filed Feb 4, 2022 18:12 UTC | ImageneBio, Inc. IKNA · Entity 7139 | GrantStock Option (Right to Buy) · Derivative | 238,900 | $0.00 Strike: $9.76 | $0.00 |
DisclosureSEC source: 0000899243-22-004884 · doc4.xml · derivative · entry 1 Manfredi Mark · CIK 0001848547 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,900 Underlying: Common Stock · 238,900 shares Expires 2032-02-03 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.